淋巴瘤免疫治疗中国专家共识(2024年版)OACSTPCD
Chinese expert consensus on immunotherapy of lymphoma(2024 edition)
淋巴瘤是一种起源于淋巴结和淋巴组织的恶性肿瘤.免疫治疗在淋巴瘤治疗领域已积累较多的临床证据和经验,但其临床规范应用尚无相关共识.因此,由中国老年保健协会肿瘤免疫治疗专业委员会牵头,组织本领域专家对淋巴瘤免疫治疗相关循证医学证据进行深入探讨,并结合专家组广泛认可的临床经验,经过多次会议讨论制定了《淋巴瘤免疫治疗中国专家共识(2024年版)》.本共识总结了单抗类药物、双特异性抗体、免疫检查点抑制剂、抗体药物偶联物、免疫调节剂和细胞治疗等免疫治疗在淋巴…查看全部>>
Lymphoma is a malignancy of the immune system originating in the lymph nodes and lymphoid tissue,has seen significant advancements in treatment through immunotherapy.There remains no relevant consensus regarding its standard clinical application in China.To address this gap,the Tumor Immunotherapy Professional Committee of China Geriatric Health Association mobilized experts from various fields to conduct a series of in-depth discussions on current evi…查看全部>>
中国老年保健协会肿瘤免疫治疗专业委员会;李志铭;张会来;周辉;吴辉菁;李玉华;姜文奇
淋巴瘤免疫治疗中国专家共识抗体细胞治疗
LymphomaImmunotherapyChinese expert consensusAntibodiesCellular therapy
《肿瘤综合治疗电子杂志》 2024 (2)
69-98,30
评论